학술논문
Overall survival with [177Lu]Lu-PSMA-617 versus cabazitaxel in metastatic castration-resistant prostate cancer (TheraP): secondary outcomes of a randomised, open-label, phase 2 trial
Document Type
Article
Author
Akhurst, Tim; Alipour, Ramin; Bailey, Dale; Banks, Patricia; Beaulieu, Alexis; Campbell, Louise; Crumbaker, Megan; Dhiantravan, Nattakorn; Hamid, Anis; Haskali, Mohammad; Hung, Terry; Kong, Grace; Lawrence, Nick; Lewin, Jeremy; McCarthy, Michael; Moodie, Kate; Murphy, Declan; Nguyen, Andrew; Pook, David; Ravi Kumar, Aravind; Roach, Paul; Roselt, Peter; Saghebi, Javad; Schembri, Geoff; Spain, Lavinia; Subramaniam, Shalini; Thang, Sue Ping; Thomas, Paul; Tran, Ben; Wallace, Roslyn; Yip, Sonia; Hofman, Michael S ; Emmett, Louise; Sandhu, Shahneen; Iravani, Amir; Buteau, James P; Joshua, Anthony M; Goh, Jeffrey C; Pattison, David A; Tan, Thean Hsiang; Kirkwood, Ian D; Ng, Siobhan; Francis, Roslyn J; Gedye, Craig; Rutherford, Natalie K; Weickhardt, Andrew; Scott, Andrew M; Lee, Sze-Ting; Kwan, Edmond M; Azad, Arun A; Ramdave, Shakher; Redfern, Andrew D; Macdonald, William; Guminski, Alex; Hsiao, Edward; Chua, Wei; Lin, Peter; Zhang, Alison Yan; Stockler, Martin R; Williams, Scott G; Martin, Andrew J; Davis, Ian D
Source
In The Lancet Oncology January 2024 25(1):99-107
Subject
Language
ISSN
1470-2045